Laboratory use of umbilical cord blood for critically ill infants

May 2014

Patrick D Carroll
Section of Neonatology,
Dixie Regional Medical Center,
Intermountain Healthcare, St. George,
UT USA 84770

Neonates nearly always experience their single largest day of blood loss on the day of birth due to admission laboratory testing. The term “admission laboratory testing” refers to the initial blood tests done when a baby is born and admitted to the NICU.

Total circulating blood volume in a 3.5 kg term newborn is 280 mL. In the smallest, sickest 0.5 kg premature newborn the circulating blood volume is only 40 mL. It is thus not surprising that phlebotomy loss has been associated with increased red cell transfusions in premature and critically ill neonates.

Recently, obtaining admission laboratory tests from the otherwise discarded fetal blood in the umbilical cord and fetal vessels on the placenta (cord blood) have been shown to decrease transfusions.

The demonstrated and potential benefits of using cord blood for admission laboratory testing in critically ill infants are an exciting development in neonatology.

Premature and critically ill infants in the NICU are frequently transfused

Rates of transfusion are higher in neonates than any other pediatric population. The smallest neonates have an exceedingly high rate of packed red blood cell (pRBC) transfusions [1]. Up to 90% of neonates less than 1 kg at birth require at least one packed red blood cell (pRBC) transfusion prior to discharge [1,2].

While erythropoietic stimulating agents [3], the practice of delayed cord clamping or umbilical cord milking [4], and restrictive transfusions guidelines [5,6] have led to a decrease in pRBC transfusion rates, the frequency and total number of transfusions remain high.

Though still controversial a Cochrane review [7] of early erythropoietin reported increased stage >3 retinopathy of prematurity and on this basis did not recommend early erythropoietin administration.
Strategies to prevent transfusion within the first week of life may provide immediate benefit and further allow time for late erythropoietin to become effective.

pRBC transfusions are associated with adverse neonatal outcomes

Complications of pRBC transfusions have been widely described in adults. Recently there have been increased reports of complications of pRBC transfusion administered to premature infants.

Recent evidence indicates that pRBC transfusions are associated with necrotizing enterocolitis (NEC) and intraventricular hemorrhage (IVH). A number of observational studies have demonstrated an association between pRBC transfusion and NEC [8], a condition that typically occurs at several weeks of life.

It has been hypothesized that NEC following pRBC transfusion follows a distinct pathological pathway. This is supported by the observation that a subset of NEC occurs within 72 hours following pRBC transfusion. It is plausible that heavy blood loss in the first days of life may contribute to this pathway.

The observation of NEC within 72 hours of pRBC transfusion has not been studied in prospective randomized controlled trials and therefore remains controversial. IVH is a condition encountered in critically ill and premature infants. IVH typically occurs within the first week of life, a time in which an infant experiences significant blood loss from phlebotomy.

Avoiding transfusion during the first week of life may be meritorious. Recent reports associate transfusions with IVH. One study [9] by Christensen et al. demonstrated a more than 50 % decrease in severe IVH from 17 % to 8 % following institution of restrictive transfusion guidelines.

Moreover, the rate of IVH was 27 % among infants receiving a transfusion in the first week of life compared to 2 % among those not receiving a transfusion. Due to the observational nature of this study, causation cannot be concluded. However, this finding compels one to consider IVH rates and the effect that lower phlebotomy loss in the first days of life could produce.

Use of cord blood for admission laboratory testing is one method to dramatically decrease phlebotomy loss during this critical period.

Use of cord blood at delivery for initial admission laboratory testing

Admission laboratory testing in premature and other critically ill infants commonly includes a complete blood count (CBC) with manual white cell differential, blood culture, blood type and screen, and mandated newborn metabolic screen.

Some institutions may obtain additional laboratory studies routinely. Chromosomes or other genetic testing is also occasionally necessary. Even without genetic testing, routine tests typically require 3 or more mL of blood.

This blood volume represents a significant percent of a critically ill, premature neonate's total circulating blood volume (Table I). Because these laboratory tests are done immediately after birth, they can be successfully obtained from cord blood in over 90 % of neonates, including neonates receiving delayed cord clamping or cord milking at birth [10].

1. Complete blood count

Obtaining a CBC with manual white cell differential is important in critically ill infants to assess risk of anemia, thrombocytopenia, and infection. Obtaining cord blood can provide these results without necessitating additional phlebotomy from the infant.

To date there are two studies comparing CBC results from paired samples of cord blood and blood from the neonate. Hansen et al. examined the correlation of I/T ratio between cord blood and neonatal blood in term infants.
They demonstrated the correlation in paired samples of white blood cell (WBC) count, hematocrit, and platelets ($r=0.70$, $0.54$, $0.65$, respectively) [11]. More recently a study of premature infants compared paired samples in a preterm population [12]. This study demonstrated a high level of agreement between cord blood samples compared to those obtained directly from the infant (Table II).

However, when the cord blood platelet count was less than 100,000/µL, there was a poor correlation with the neonatal platelet count, suggesting that clotting of the cord blood may occur before sampling in some cases, and that low platelet counts from cord blood should be repeated after birth.

This study also reported that the mean WBC count, though not paired samples, from different neonatal sources varied significantly (i.e., capillary, radial arterial, umbilical venous, umbilical arterial), leading one to question whether currently accepted sources for the admission CBC should be interpreted with the same reference values or have their own source-specific reference values.

<table>
<thead>
<tr>
<th>Test volume (mL)*</th>
<th>Percent of circulating blood volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infant birth weight</td>
<td>Infant birth weight</td>
</tr>
<tr>
<td></td>
<td>500 g</td>
</tr>
<tr>
<td>Blood culture</td>
<td>1</td>
</tr>
<tr>
<td>CBC/diff</td>
<td>0.3</td>
</tr>
<tr>
<td>Type and screen</td>
<td>1</td>
</tr>
<tr>
<td>Newborn metabolic screen</td>
<td>0.6</td>
</tr>
<tr>
<td>Chromosomes/microarray</td>
<td>3</td>
</tr>
<tr>
<td>TOTAL</td>
<td>5.9</td>
</tr>
</tbody>
</table>

*Minimum recommended volume. Some labs may require different minimum volumes.

TABLE I: Percent of circulating blood volume required for laboratory testing in neonates of various birth weight

<table>
<thead>
<tr>
<th>White blood cell count (x 1,000 cells/µL)</th>
<th>Fetal cord blood</th>
<th>Neonatal admission blood</th>
<th>Difference (95% CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capillary (n=18)</td>
<td>9.5</td>
<td>14.1</td>
<td>4.6 (3.1, 6.0)</td>
</tr>
<tr>
<td>Radial artery (n=25)</td>
<td>8.6</td>
<td>11.4</td>
<td>2.8 (1.5, 4.0)</td>
</tr>
<tr>
<td>Umbilical venous catheter (n=58)</td>
<td>8.3</td>
<td>9.5</td>
<td>1.2 (0.5, 1.9)</td>
</tr>
<tr>
<td>Umbilical arterial catheter (n=38)</td>
<td>7.4</td>
<td>10.3</td>
<td>2.9 (1.7, 4.1)</td>
</tr>
<tr>
<td>All sources (n=139)</td>
<td>8.3</td>
<td>10.7</td>
<td>2.4 (1.9, 2.9)</td>
</tr>
</tbody>
</table>

| Hemoglobin (g/dL)                         |                   |                          |                      |
| Arterial and venous specimen (n=146)      | 14.5              | 15.1                     | 0.6 (0.3, 0.9)       |
| All sources (n=174)                      | 14.5              | 15.5                     | 1.0 (0.7, 1.2)       |

| Platelet count (x 1,000 cells/µL)         |                   |                          |                      |
| All sources (n=141)                      | 224               | 230                      | 6 (-4, 15)           |

Adapted with permission from Carroll et al. [12]

TABLE II: Paired comparison of white blood cell, hemoglobin, hematocrit, and platelet count in fetal cord blood and neonatal admission blood.
2. Blood culture

The majority of neonates admitted to the NICU require a blood culture on admission as they often have respiratory distress, sometimes caused by infection. Blood cultures require more blood volume than any other laboratory test commonly done on admission, with genetic testing as a rare exception.

It is common for neonatologists to decrease the blood culture volume to 0.5 mL in the smallest neonates to minimize phlebotomy loss. This strategy increases the risk of false negative results [13]. In contrast, utilizing cord blood immediately after delivery offers clinicians the opportunity to increase the volume of the blood culture, thereby decreasing the chance for a false negative result.

Herson et al. [14] demonstrated a five-fold increase in true positives when the blood culture volume was increased to 5 mL and obtained from the cord blood among high-risk premature infants. Other studies, too, have found an increase, though less dramatic, in the frequency of true positive blood cultures from cord blood (Table III).

Greater sensitivity due to higher volume of blood cultures from cord blood may prevent unnecessary prolongation of antibiotic treatment course. Of great concern to clinicians is a contaminated blood culture from any source. In this regard, it is important to remember that:

1. The umbilical cord and fetal side of the placenta is bathed in the same amniotic fluid as the fetus.
2. The placenta is delivered in the same manner as the fetus, whether through the vaginal canal or abdominal incision. This exposes the umbilical cord and placenta to the same pathogens as the fetus at the time of delivery.
3. Cord blood remains isolated from maternal blood by the trophoblastic membrane.
4. Betadine or chlorhexidine must dry to be effective. This is true whether used on the neonate or placenta/umbilical cord.

Remembering these principles will guide those obtaining adequate cord blood cultures.

3. Blood type and screen

The American Association of Blood Banks [15] states, "Initial [neonatal] testing must include ABO and D typing of their red cells and a screen for unexpected red cell antibodies, using either plasma or serum from the infant or mother." Among tests done on the neonate following delivery, clinicians have the greatest experience with utilizing cord blood for a type and antibody testing.

Blood type and antibody testing can be performed using cord blood. Extreme caution must be taken in obtaining this sample. If the needle is near placental tissue, user error may result in improperly obtaining maternal blood

<table>
<thead>
<tr>
<th>Culture volume</th>
<th>Cord/placental cultures</th>
<th>Patient cultures</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>Positive cultures</td>
</tr>
<tr>
<td>Polin (1981)</td>
<td>&gt;2 mL</td>
<td>200</td>
</tr>
<tr>
<td>Herson (1998)</td>
<td>High risk</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Medium risk</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>Low risk</td>
<td>20</td>
</tr>
<tr>
<td>Hansen (2005)</td>
<td>&gt;1 mL</td>
<td>113</td>
</tr>
<tr>
<td>Total</td>
<td>394</td>
<td>16</td>
</tr>
</tbody>
</table>

TABLE III: Comparison of blood cultures obtained from the umbilical cord/placenta and postnatal neonatal sampling. Reprinted from Carroll PD, Widness JA. Nonpharmacological, blood conservation techniques for preventing neonatal anemia – effective and promising strategies for reducing transfusion. Semin Perinatol 2012; 36,4: 232-43, with permission from Elsevier [18].
from the intervillous space rather than fetal blood from fetal vessels on the placenta. Discussions with local blood banks can help guide the clinician on when cord blood may be appropriate for type and screen in anticipation of transfusion.

4. Newborn metabolic screen

Each state has established its own requirements for newborn metabolic screening. This testing aims to identify metabolic or genetic conditions that, when identified before symptomatic, can be treated, thereby preventing or delaying complications, including mental retardation and death. Variability exists in the number, frequency, and timing of testing.

This variability increases the challenge with regard to optimal timing of screening. Current guidelines published by the Clinical and Laboratory Standards Institute recommend [16] for premature, low-birth-weight, or sick infants “serial dried blood spot screening with the first screen obtained on admission.”

Obtaining the first newborn metabolic screen from cord blood is accurate for hemoglobinopathies, biotinidase deficiency, galactosemia, and fatty acid oxidation disorders. Other conditions may yield false positive or negative results, whether the sample immediately after birth is from cord blood or blood directly from the neonate.

This is particularly true for cystic fibrosis (false positive) and hypothyroidism (false negative). Repeat testing at a later date is required to more adequately screen for these disorders.

5. Cord pH and blood gas

Obtaining a cord blood gas including pH, oxygen and carbon dioxide measurements can provide valuable information, particularly when there is concern for fetal distress or perinatal asphyxia [17]. Blood from the umbilical artery is the preferred source to assess neonatal status at delivery.

This is due to the fetal circulation pattern of oxygenated blood entering the fetus via the umbilical vein and leaving the fetus via the umbilical artery following oxygen extraction in fetal tissue. Similarly, the pH of umbilical arterial blood is more reflective of fetal acid-base status than umbilical venous blood.

Although it is possible to obtain neonatal admission laboratory tests from umbilical arterial blood, it has been more often obtained from umbilical venous blood. Therefore, arterial cord gasses are generally obtained separately.

Obtaining neonatal admission laboratory studies from umbilical cord blood does not interfere with the ability to obtain umbilical arterial cord blood gas.

Use of cord blood decreases neonatal transfusions

Two studies report using cord blood to replace routine neonatal phlebotomy at the time of admission to the NICU. In 2011 Christensen et al. [18] reported a feasibility study in which 10 infants had all admission laboratory tests performed on cord blood. These infants were matched by birth weight, gestational age, gender, and race with concurrent controls.

Neonates for whom admission laboratory studies came from cord blood were less likely to receive a pRBC transfusion within the first 72 hours of life (1 vs. 5; p=0.14) and within the first 7 days (4 vs. 16 transfusions; p=0.02). This practice also was associated with a lower incidence of IVH (0 vs. 4 cases; p=0.01).

The mean volume of transfused blood was lower in the study arm (21.5 vs. 5.1 mL; p=0.04). This feasibility study led to a larger multicenter study [10] that demonstrated cord labs could be obtained at a high rate (91 out of 96 eligible) among VLBW infants in three NICUs.

In this study, cases were matched with historical controls. Neonates for whom admission laboratory studies were obtained from cord blood had increased hemoglobin levels in the first 24 hours, lower rate of vasopressor use, and fewer pRBC transfusions (Table IV).
The rate of severe IVH (Grade >3) did not reach the level of statistical significance between the study arms (12 % of cases vs. 21 % of controls; p=0.115). These two studies provide compelling evidence that obtaining admission laboratory studies from cord blood immediately after delivery is not only feasible but beneficial. Randomized controlled trials are needed to better establish this practice.

**Technique for drawing cord blood**

The process for drawing cord blood for admission laboratory studies is quite simple. It is important to remind the obstetrician to clamp the placental side of the umbilical cord so blood does not drain out prior to collection. Cord blood should be obtained shortly after the placenta is delivered.

Several techniques have been described, including using an umbilical cord segment prepared with alcohol [11], or accessing the vessels directly on the placental surface [14]. We recommend preparing the placental surface and base of the umbilical cord with betadine.

We then recommend insertion of an 18-gauge needle with the bevel down attached to a 10 mL syringe into a pre-identified large vein near the umbilical cord insertion on the placenta (Video Link).

Once the blood is collected, it can be transferred in a sterile manner into a blood culture bottle (first), EDTA microsampling tube for CBC and type and screen, sodium-heparin tube for chromosomes, if needed, and directly onto filter paper for newborn metabolic screen according to state regulations.

**Conclusion**

Significant progress has been made in utilizing placental blood for admission laboratory testing to lessen the need for pRBC transfusions in premature and other critically ill newborns. This practice has shown to be practical, feasible, and anatomically/physiologically sound. Placental labs can be obtained even after delayed cord clamping or cord milking.

The potential of placental labs resulting in decreased IVH and/or NEC is encouraging but unproven. Data showing decreased number and frequency of transfusions in the first 7 days of life following utilization of placental labs is compelling. We therefore recommend that those caring for critically ill and premature newborns strongly consider adopting this practice.
We appreciate Pamela Kling, MD for review of this manuscript and Mark Hart for valuable editorial and secretarial assistance.

References


18. Christensen RD, Lambert DK, Baer VL, et al. Postponing or eliminating red blood cell transfusions of very low birth weight neonates by obtaining all baseline laboratory blood tests from otherwise discarded fetal blood in the placenta. Transfusion 2011; 51,2: 253-58.